Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Engin Ayturk, is a Senior Manager at Biogen, leading the Cambridge Process Biochemistry (PBC) small and pilot scale purification development teams, and responsible for the development of purification processes for clinical and commercial biologics programs.
• Previously as a Sr. R&D Manager at Pall Life Sciences, Dr. Ayturk led the BioPharm Applications R&D Integrated Continuous BioProcessing team and the Filtration Groups for the development and commercialization of next generation novel bioprocess platforms and technologies.
• In addition to his primary focus on product, process and technology development, characterization, scale-up and tech transfer, Dr. Ayturk brings a strong emphasis on process modeling, bioprocess economics and the development of process control strategies for various technologies and is well recognized for cross-functional team leadership, internal/external collaborations and partnerships management as has numerous business certifications on project and people management, agile product development and innovation coaching modules.
• Dr. Ayturk holds M.Sc. and Ph.D. degrees both in Chemical Engineering and previously worked as a Research Assistant Professor at Worcester Polytechnic Institute (WPI).
Capacity and beyond: Evaluation of a next generation protein A resin
Protein A chromatography, an affinity-based purification method that selectively binds antibodies, is generally considered as one of the most expensive steps in a downstream process due to the high cost of protein A resin. Decreasing the effective cost of the protein A step can be accomplished by increasing the amount of antibody that is processed per column cycle, either by increasing resin capacity or enhancing resin utilization through processing strategies such as continuous chromatography. Additionally, increasing the number of times a column is cycled can drive down the protein A cost per batch.
Here, we discuss the evaluation of a next generation protein A resin (MabSelect PrismA) with increased capacity and base-stability relative to other commercially available resins. Dynamic binding capacity and purification performance at different loads were determined for several monoclonal antibodies on both a current generation protein A resin (MabSelect SuRe LX) and MabSelect PrismA. The impact of increased column loading on elution peak width and eluate pool pH were further investigated. Cycling studies with representative cell culture material were also planned to assess whether increased resin lifetime could be achieved with MabSelect PrismA by utilizing a more stringent cleaning approach. Finally, an evaluation of continuous processing productivity was performed to maximize productivity and yield, while maintaining comparable product quality to batch purification. The results from the aforementioned studies provide evidence for a benefit of implementing MabSelect PrismA, through cost and productivity analyses for different processing scenarios